Skip to main content
Premium Trial:

Request an Annual Quote

Genops Bioinformatics and Samsung Enter Asia/Oceania Sales and Marketing Agreement

NEW YORK, Sept. 10 - Genops Bioinformatics signed an exclusive sales and marketing arrangement with Samsung Corp. for the Asia/Oceania market, the company announced Monday.

Under the partnership, Samsung Corp. will spearhead sales, marketing, and customer relations for Genops’ Ngene bioinformatics platform in the region. Samsung will also provide high-performance hardware and consulting services under the collaboration. Genops, based in Vancouver, BC, Canada, said the companies would share responsibility for ongoing product trials and administration.  

Han Yu, president of Genops, said a revenue-sharing model is in place “that serves both companies well.” Further financial terms of the agreement were not disclosed. 

Samsung’s prominent position in the Asia information technology market “will serve as a springboard for future product development and growth strategies in the area,” Yu said in a statement.

Last week, Genops announced a partnership with bioinformatics infrastructure provider Zerosum of Seven Valleys, Penn., to support the access, infrastructure, and delivery of Ngene.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.